Morning Overview on MSN

The FDA approved a lower-dose contrast agent to cut patients’ exposure during MRI scans

Patients who need repeated MRI scans with contrast dye could soon receive a fraction of the gadolinium they currently get. The FDA approved gadoquatrane, a new gadolinium-based contrast agent designed ...
Neurology Advisor

FDA Approves Lower-Dose Gadolinium Contrast Agent Ambelvist

The FDA has approved Bayer’s Ambelvist (gadoquatrane), the lowest-dose macrocyclic GBCA for adult and pediatric contrast-enhanced CNS and body MRI exams.
Case Western Reserve University

MRI Contrast Agents Accumulate in the Brain

The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast ...
Las Vegas Sun

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and ...

AMBELVIST ® (gadoquatrane) is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and ...

From X-rays to MRI: Five Imaging Tests, Their Differences, and Precautions

Sportschosun, Jang Jong-ho] Imaging tests are a key tool in modern medicine for accurately diagnosing diseases and ...
Healio

FDA approves Ambelvist MRI contrast agent with lower dose of gadolinium

The FDA has approved Ambelvist, a macrocyclic gadolinium-based option for contrast-enhanced MRI, now the lowest ...